<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1024-0675</journal-id>
<journal-title><![CDATA[Revista de la Sociedad Boliviana de Pediatría]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. bol. ped.]]></abbrev-journal-title>
<issn>1024-0675</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Boliviana de Pediatría]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1024-06752002000300011</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Ventilação de alta freqüência por oscilação comparada a ventilação mecânica convencional associada a reposição de surfactante em coelhos]]></article-title>
<article-title xml:lang="en"><![CDATA[High frequency oscillation ventilation compared to conventional mechanical ventilation plus exogenous surfactant replacement in rabbits]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Piva]]></surname>
<given-names><![CDATA[Jefferson]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chatrkaw]]></surname>
<given-names><![CDATA[Phornlert]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Choong]]></surname>
<given-names><![CDATA[Karen]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Frndova]]></surname>
<given-names><![CDATA[Helena]]></given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cox]]></surname>
<given-names><![CDATA[Peter]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,University of Toronto Hospital for Sick Children and School of Medicine Department of Critical Care Medicine]]></institution>
<addr-line><![CDATA[Toronto ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2002</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2002</year>
</pub-date>
<volume>41</volume>
<numero>3</numero>
<fpage>154</fpage>
<lpage>160</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S1024-06752002000300011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S1024-06752002000300011&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S1024-06752002000300011&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Objetivos: a) avaliar o efeito na oxigenação e ventilação de coelhos artificialmente depletados de surfactante quando submetidos à ventilação mecânica convencional associada à reposição parcial de surfactante exógeno; b) comparar a evolução deste grupo com outro grupo submetido à ventilação de alta freqüência por oscilação (HFO) sem reposição associada de surfactante. Métodos: Vinte coelhos brancos da raça New Zealand, peso de + 3 kg, foram anestesiados e artificialmente induzidos à depleção de surfactante endógeno através de sucessivas lavagens pulmonares com alíquotas (25 ml/kg) de solução fisiológica, até atingir uma PaO2 menor que 100 mmHg, quando ventilados via traqueostomia no modo de pressão controlada objetivando um volume corrente de 10ml/kg, com PEEP de 5cm H2O, FiO2 de 100%, freqüência respiratória de 30 mpm, e tempo inspiratório de 0,65 s. Posteriormente, os coelhos foram divididos em (a) grupo CMV+S, submetido à ventilação convencional associada com reposição parcial de surfactante exógeno; (b) grupo HFO submetido à ventilação de alta freqüência por oscilação. Gasometrias arteriais foram coletadas antes da lavagem pulmonar, após a lavagem pulmonar, 15, 60 e 120 minutos após iniciado o tratamento. Os grupos foram comparados utilizando-se o teste t de Student. Resultados: Em ambos grupos a PaO2 (pós lavagem pulmonar) era inferior a 50mmHg (p=0,154), subindo aos15 minutos de tratamento para 254 mmHg (CMV+S) e 288 mmHg (HFO, p=0,626). Aos 60 e 120 minutos, a PaO2 foi maior (p=0,001) no grupo HFO (431 e 431 mmHg) quando comparado com o grupo CMV+S, que apresentou queda progressiva (148 e 126 mmHg). Aos 60 minutos a PaCO2 era significativamente menor no grupo do CMV+S (29 versus 41 mmHg). Conclusões: Em modelo animal com SARA a estratégia de ventilação protetora como a HFO, isoladamente, promove uma rápida e persistente melhora na oxigenação, inclusive, com níveis superiores aos obtidos pelos animais submetidos à ventilação mecânica convencional associada à reposição de surfactante.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Objectives: (a) to evaluate the effect on oxygenation and ventilation of rabbits with induced surfactant depletion when they are submitted to a conventional mechanical ventilation, plus a small dose of exogenous surfactant; (b) to compare this group with another group submitted to a High Frequency Oscillation (HFO) without exogenous surfactant administration. Methods: Twenty New Zealand White rabbits weighing (+ 3 kg) were anaesthetized and artificially induced to a endogenous surfactant depletion by successively lung lavage with normal saline (aliquots of 25 ml/kg) until to reach a persistent PaO2 less than 100 mmHg when submitted to a mechanical ventilation in a pressure control mode with a target tidal volume of 10ml/kg, PEEP of 5cm H2O, FiO2 1.0, respiratory rate 30/min, and inspiratory time of 0.65 s. Then the rabbits were divided in (a) CMV+S group, submitted to a conventional mechanical ventilation plus exogenous surfactant replacement; (b) HFO group, submitted to a High Frequency Oscillation Ventilation. Arterial blood gases were measured at control period, post lung lavage, 15, 16 and 120 minutes after treatment started. The groups were compared using Student t test. Results: The post lung lavage PaO2 in both groups was lower than 50mmHg (p=0.154), increasing after 15 min of treatment to 254 mmHg (CMV+S) and 288 mmHg (HFO, p=0.626). The PaO2 at 60 and 120 minutes were higher (p=0.001) in the HFO group (431 e 431 mmHg) when compared with the CMV+S group, which showed a progressive fall (148 e 126 mmHg). At 60 minutes of treatment, the PaCO2 was lower (p=0.008) in the CMV+S group (29 versus 41 mmHg). Conclusions: In ARDS animal model a protect mechanical ventilation strategy as HFO by itself promotes a fast and persistent increase in the oxygenation, with superior levels than those observed in animals treated with conventional mechanical ventilation plus exogenous surfactant replacement.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[J. pediatr. (Rio J.) 2000]]></kwd>
<kwd lng="pt"><![CDATA[76 (5): 349-356]]></kwd>
<kwd lng="pt"><![CDATA[tensoativos]]></kwd>
<kwd lng="pt"><![CDATA[respiração artificial]]></kwd>
<kwd lng="pt"><![CDATA[anoxemia]]></kwd>
<kwd lng="pt"><![CDATA[insuficiência respiratória]]></kwd>
<kwd lng="en"><![CDATA[J. pediatr. (Rio J.) 2000]]></kwd>
<kwd lng="en"><![CDATA[76 (5): 349-356]]></kwd>
<kwd lng="en"><![CDATA[surface-active agents]]></kwd>
<kwd lng="en"><![CDATA[artificial respiration]]></kwd>
<kwd lng="en"><![CDATA[hypoxemia]]></kwd>
<kwd lng="en"><![CDATA[respiratory insufficiency]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[  <B></B>     <P ALIGN="right"><b><font size="2" face="Verdana, Arial, Helvetica, sans-serif">ARTICULOS DEL CONO SUR - BRASIL</font></b></P>     <P ALIGN="left"><font face="Verdana, Arial, Helvetica, sans-serif"><b><font size="4">Ventila&ccedil;&atilde;o de alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o comparada a ventila&ccedil;&atilde;o mec&acirc;nica convencional associada a reposi&ccedil;&atilde;o de surfactante em coelhos<sup>(1)</sup></font></b></font><FONT FACE="Verdana" SIZE=2>   </FONT> </P>     <P ALIGN="left"><font size="3" face="Verdana"><strong><em>High frequency oscillation ventilation compared to conventional mechanical ventilation plus exogenous surfactant replacement in rabbits</em></strong></font></P>     <P ALIGN="left"><font size="2" face="Verdana"><strong>Jefferson Piva*, Phornlert Chatrkaw**, Karen Choong***, Helena Frndova****, Peter Cox*****    <br> </strong></font><FONT FACE="Verdana" SIZE=1><I>    <br>   * Professor visitante.    <br>   ** P&oacute;s-graduando em pesquisa.    <br>   *** P&oacute;s-graduando em cl&iacute;nica.    <br>   **** Engenheira biom&eacute;dica.    ]]></body>
<body><![CDATA[<br>   ***** Diretor cl&iacute;nico. Department of Critical Care Medicine (Pediatric Intensive Care), Hospital for Sick Children and School of Medicine of The University of Toronto.    <br> Pesquisa patrocinada pelo Department of Critical Care Medicine, Hospital for Sick Children, Toronto, Canad&aacute;.</i></font></P>     <P ALIGN="left"><FONT FACE="Verdana" SIZE=1><I><strong>(1) Art&iacute;culo original de Brasil, publicado en el Jornal de Pediatr&iacute;a el 2000; 76 (5): 349-356 y que fue seleccionado para su reproducci&oacute;n en el VI encuentro de Editores del Cono Sur, Bolivia, 2001</strong></i></font></P> <hr> <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>Resumo</strong></font><FONT FACE="Verdana" SIZE=2>     <P ALIGN="JUSTIFY"><I><strong>Objetivos:</strong></i> a) avaliar o efeito na oxigena&ccedil;&atilde;o e ventila&ccedil;&atilde;o de coelhos artificialmente depletados de surfactante quando submetidos &agrave; ventila&ccedil;&atilde;o mec&acirc;nica convencional associada &agrave; reposi&ccedil;&atilde;o parcial de surfactante ex&oacute;geno; b) comparar a evolu&ccedil;&atilde;o deste grupo com outro grupo submetido &agrave; ventila&ccedil;&atilde;o de alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o (HFO) sem reposi&ccedil;&atilde;o associada de surfactante. </P>     <P ALIGN="JUSTIFY"><I><strong>M&eacute;todos:</strong></i> Vinte coelhos brancos da ra&ccedil;a New Zealand, peso de + 3 kg, foram anestesiados e artificialmente induzidos &agrave; deple&ccedil;&atilde;o de surfactante end&oacute;geno atrav&eacute;s de sucessivas lavagens pulmonares com al&iacute;quotas (25 ml/kg) de solu&ccedil;&atilde;o fisiol&oacute;gica, at&eacute; atingir uma PaO2 menor que 100 mmHg, quando ventilados via traqueostomia no modo de press&atilde;o controlada objetivando um volume corrente de 10ml/kg, com PEEP de 5cm H2O, FiO2 de 100%, freq&uuml;&ecirc;ncia respirat&oacute;ria de 30 mpm, e tempo inspirat&oacute;rio de 0,65 s. Posteriormente, os coelhos foram divididos em (a) grupo CMV+S, submetido &agrave; ventila&ccedil;&atilde;o convencional associada com reposi&ccedil;&atilde;o parcial de surfactante ex&oacute;geno; (b) grupo HFO submetido &agrave; ventila&ccedil;&atilde;o de alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o. Gasometrias arteriais foram coletadas antes da lavagem pulmonar, ap&oacute;s a lavagem pulmonar, 15, 60 e 120 minutos ap&oacute;s iniciado o tratamento. Os grupos foram comparados utilizando-se o teste t de Student. </P> <I></I>     <P ALIGN="JUSTIFY"><I><strong>Resultados:</strong></i> Em ambos grupos a PaO2 (p&oacute;s lavagem pulmonar) era inferior a 50mmHg (p=0,154), subindo aos15 minutos de tratamento para 254 mmHg (CMV+S) e 288 mmHg (HFO, p=0,626). Aos 60 e 120 minutos, a PaO2 foi maior (p=0,001) no grupo HFO (431 e 431 mmHg) quando comparado com o grupo CMV+S, que apresentou queda progressiva (148 e 126 mmHg). Aos 60 minutos a PaCO2 era significativamente menor no grupo do CMV+S (29 versus 41 mmHg). </P>     <P ALIGN="JUSTIFY"><I><strong>Conclus&otilde;es:</strong></i> Em modelo animal com SARA a estrat&eacute;gia de ventila&ccedil;&atilde;o protetora como a HFO, isoladamente, promove uma r&aacute;pida e persistente melhora na oxigena&ccedil;&atilde;o, inclusive, com n&iacute;veis superiores aos obtidos pelos animais submetidos &agrave; ventila&ccedil;&atilde;o mec&acirc;nica convencional associada &agrave; reposi&ccedil;&atilde;o de surfactante. <I> </I></P> <I>    <P ALIGN="JUSTIFY"><strong>Palabras Claves: </strong></P> </I>     <P ALIGN="JUSTIFY">J. pediatr. (Rio J.) 2000; 76 (5): 349-356: tensoativos, respira&ccedil;&atilde;o artificial, anoxemia, insufici&ecirc;ncia respirat&oacute;ria.<B> </B></P> </FONT> <hr> <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>Abstract</strong></font><FONT FACE="Verdana" SIZE=2>     <P ALIGN="JUSTIFY"><I><strong>Objectives:</strong></i> (a) to evaluate the effect on oxygenation and ventilation of rabbits with induced surfactant depletion when they are submitted to a conventional mechanical ventilation, plus a small dose of exogenous surfactant; (b) to compare this group with another group submitted to a High Frequency Oscillation (HFO) without exogenous surfactant administration. </P>     ]]></body>
<body><![CDATA[<P ALIGN="JUSTIFY"><I><strong>Methods:</strong></i> Twenty New Zealand White rabbits weighing (+ 3 kg) were anaesthetized and artificially induced to a endogenous surfactant depletion by successively lung lavage with normal saline (aliquots of 25 ml/kg) until to reach a persistent PaO2 less than 100 mmHg when submitted to a mechanical ventilation in a pressure control mode with a target tidal volume of 10ml/kg, PEEP of 5cm H2O, FiO2 1.0, respiratory rate 30/min, and inspiratory time of 0.65 s. Then the rabbits were divided in (a) CMV+S group, submitted to a conventional mechanical ventilation plus exogenous surfactant replacement; (b) HFO group, submitted to a High Frequency Oscillation Ventilation. Arterial blood gases were measured at control period, post lung lavage, 15, 16 and 120 minutes after treatment started. The groups were compared using Student t test. </P>     <P ALIGN="JUSTIFY"><I><strong>Results:</strong></i> The post lung lavage PaO2 in both groups was lower than 50mmHg (p=0.154), increasing after 15 min of treatment to 254 mmHg (CMV+S) and 288 mmHg (HFO, p=0.626). The PaO2 at 60 and 120 minutes were higher (p=0.001) in the HFO group (431 e 431 mmHg) when compared with the CMV+S group, which showed a progressive fall (148 e 126 mmHg). At 60 minutes of treatment, the PaCO2 was lower (p=0.008) in the CMV+S group (29 versus 41 mmHg). </P>     <P ALIGN="JUSTIFY"><I><strong>Conclusions:</strong></i> In ARDS animal model a protect mechanical ventilation strategy as HFO by itself promotes a fast and persistent increase in the oxygenation, with superior levels than those observed in animals treated with conventional mechanical ventilation plus exogenous surfactant replacement.</P> <I>    <P ALIGN="JUSTIFY"><strong>Keywords: </strong></P> </I>     <P ALIGN="JUSTIFY">J. pediatr. (Rio J.) 2000; 76 (5): 349-356: surface-active agents, artificial respiration, hypoxemia, respiratory insufficiency.</P> </FONT> <hr> <strong><font size="3" face="Verdana, Arial, Helvetica, sans-serif">    <br> Introdu&ccedil;&atilde;o</font></strong><FONT FACE="Verdana" SIZE=2>     <P ALIGN="JUSTIFY">Na S&iacute;ndrome do Desconforto (<em>Ang&uacute;stia</em>) Respirat&oacute;rio Agudo (SDRA/ SARA) o comprometimento pulmonar n&atilde;o ocorre de forma homog&ecirc;nea, havendo &aacute;reas com complac&ecirc;ncia muito reduzida em oposi&ccedil;&atilde;o a outras com complac&ecirc;ncia pr&oacute;xima do normal<sup>(1,2)</sup>. Como conseq&uuml;&ecirc;ncia h&aacute; uma diminui&ccedil;&atilde;o progressiva do volume pulmonar, sendo por este motivo que os pulm&otilde;es na SARA t&ecirc;m sido preferentemente definidos como "pequenos" em substitui&ccedil;&atilde;o &agrave; denomina&ccedil;&atilde;o de "pulm&otilde;es duros" (<em>stiff lungs</em>) usados no passado<sup>(3)</sup>. </P>     <P ALIGN="JUSTIFY">Embora a ventila&ccedil;&atilde;o mec&acirc;nica seja necess&aacute;ria para manter a vida de pacientes com SARA, o espec&iacute;fico m&eacute;todo ou padr&atilde;o ideal de ventila&ccedil;&atilde;o ainda permanece a ser definido. </P>     <P ALIGN="JUSTIFY">Dependendo do padr&atilde;o ventilat&oacute;rio adotado, pode-se induzir a les&otilde;es pulmonares progressivas. A t&eacute;cnica usada para ventilar &aacute;reas de "baixa complac&ecirc;ncia" pode n&atilde;o ser apropriada para ventilar &aacute;reas com "complac&ecirc;ncia normal", podendo, nestas regi&otilde;es, induzir a dano pulmonar (<em>VILI -Ventilator Induced Lung Injury</em>)<sup>(2-6)</sup>. </P>     <P ALIGN="JUSTIFY">Les&atilde;o pulmonar induzida pelo ventilador na SARA tem sido associado com a) <em>barotrauma</em>, quando a press&atilde;o excessiva utilizada durante a ventila&ccedil;&atilde;o mec&acirc;nica causa escapes de ar (pneumot&oacute;rax, enfisema intersticial, pneumomediastino,...); b) <em>volutrauma</em>, quando o volume corrente administrado distende preferentemente &aacute;reas com complac&ecirc;ncia normal ou aumentada, ocasionando estiramento e ruptura tecidual, seguida de extravasamento capilar, edema alveolar, anormalidades na produ&ccedil;&atilde;o e distribui&ccedil;&atilde;o do surfactante; c) <em>atelectrauma</em>, &eacute; a les&atilde;o pulmonar relacionada com abertura e fechamento (colapso e distens&atilde;o) de unidades alveolares. Neste caso, os pulm&otilde;es s&atilde;o ventilados usando baixos volumes correntes, inferiores ao ponto de inflex&atilde;o da curva press&atilde;o volume, e/ou a press&atilde;o no final da expira&ccedil;&atilde;o n&atilde;o &eacute; capaz de manter as vias a&eacute;reas terminais e alv&eacute;olos abertos, levando a progressivo colapso pulmonar, sendo que, para reabrir estas unidades, uma press&atilde;o maior ser&aacute; necess&aacute;ria; d) <em>biotrauma</em>, quando a ventila&ccedil;&atilde;o mec&acirc;nica causa colapso, estiramento ou ruptura tecidual pulmonar levando a dano celular com aumento dos mediadores inflamat&oacute;rios locais (citoquinas, radicais livres de oxig&ecirc;nio,...)<sup>(2,4-7)</sup>. </P>     ]]></body>
<body><![CDATA[<P ALIGN="JUSTIFY">Durante os &uacute;ltimos anos houve v&aacute;rios estudos demonstrando a import&acirc;ncia da utiliza&ccedil;&atilde;o de t&eacute;cnicas protetoras de ventila&ccedil;&atilde;o mec&acirc;nica em pacientes com SARA, reduzindo a incid&ecirc;ncia de les&atilde;o pulmonar induzida pelo ventilador e influindo na sobrevida<sup>(8,9)</sup>. </P>     <P ALIGN="JUSTIFY">Nos pacientes com SARA, ocorre tamb&eacute;m disfun&ccedil;&atilde;o do surfactante, promovendo instabilidade das unidades, alveolares favorecendo ao seu colabamento<sup>(3,5,6,10)</sup>. A ventila&ccedil;&atilde;o protetora nesta situa&ccedil;&atilde;o baseia-se em aumentar o volume expirat&oacute;rio pulmonar (por exemplo, aumentando a press&atilde;o expirat&oacute;ria positiva final &shy; PEEP) para evitar o colapso alveolar, assim como usar baixos volumes correntes prevenindo a hiperinsufla&ccedil;&atilde;o (distens&atilde;o) alveolar. Estrat&eacute;gias envolvendo a manobra de recrutamento, mantendo volume pulmonar as custas de PEEP, uso associado de surfactante, ventila&ccedil;&atilde;o l&iacute;quida, ou ventila&ccedil;&atilde;o por oscila&ccedil;&atilde;o com uma press&atilde;o de vias a&eacute;reas superior a utilizada na ventila&ccedil;&atilde;o convencional podem reduzir a les&atilde;o pulmonar induzida pela ventila&ccedil;&atilde;o, promover uma insufla&ccedil;&atilde;o alveolar mais fisiol&oacute;gica e reduzir a inflama&ccedil;&atilde;o pulmonar<sup>(2,5,7-9,11-15)</sup>. </P>     <P ALIGN="JUSTIFY">A ventila&ccedil;&atilde;o em alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o (<em>High Frequency Oscillation - HFO</em>) foi desenvolvida cerca de 50 anos atr&aacute;s e baseia-se em utilizar diminutos volumes correntes mantendo constante a press&atilde;o m&eacute;dia das vias a&eacute;reas, evitando desta forma volumes pulmonares extremos (baixos e elevados)<sup>(13,16-18)</sup>. V&aacute;rios autores puderam demonstrar em diferentes modelos animais que a HFO pode proteger os pulm&otilde;es de les&atilde;o induzida quando comparada com ventila&ccedil;&atilde;o convencional<sup>11,17,19,20</sup>. Apesar dos estudos cl&iacute;nicos em humanos serem ainda controversos, a HFO vem sendo reconhecida com uma alternativa eficaz para ser empregada em insufici&ecirc;ncia respirat&oacute;ria da crian&ccedil;a e do rec&eacute;m nascido. Estudos cl&iacute;nicos t&ecirc;m sugerido que a HFO estaria associada como uma menor incid&ecirc;ncia de les&atilde;o pulmonar induzida que a ventila&ccedil;&atilde;o convencional<sup>(5,13,16,18,21)</sup>.</P>     <P ALIGN="JUSTIFY">Em modelos animais com SARA, a les&atilde;o pulmonar induzida pelo ventilador p&ocirc;de ser evitada quando administrouse surfactante ex&oacute;geno associado com PEEP de 4 cmH2O<sup>(11,14,15,22,23)</sup>. Entretanto, o uso de surfactante ex&oacute;geno em s&eacute;ries cl&iacute;nicas de pacientes com SARA tem apresentado resultados controversos<sup>18,24,25</sup>. Esses diferentes resultados podem ser atribu&iacute;dos aos seguintes fatores: a) tipo e origem do surfactante utilizado; b) m&eacute;todo de administra&ccedil;&atilde;o do surfactante; c) dose e fase da doen&ccedil;a em que o surfactante foi administrado; d) presen&ccedil;a de prote&iacute;nas inibidoras na via a&eacute;rea terminal; e d) estrat&eacute;gia ventilat&oacute;ria utilizada concomitante com a administra&ccedil;&atilde;o de surfactante<sup>(14,15,24,26)</sup>. </P>     <P ALIGN="JUSTIFY">O surfactante alveolar existe sob duas distintas formas estruturais: a) grandes agregados (ativa); e b) pequenos agregados (inativo)<sup>(14,15,24,27)</sup>. O surfactante ex&oacute;geno consiste basicamente da forma de grandes agregados. Uma vez depositado no pulm&atilde;o o surfactante ex&oacute;geno pode ser convertido na forma inativa. Tem-se demonstrado que a utiliza&ccedil;&atilde;o de volumes correntes pequenos durante a ventila&ccedil;&atilde;o mec&acirc;nica &eacute; uma das melhores formas de preservar o surfactante end&oacute;geno<sup>(12,14,15,17)</sup>. Por outro lado, a utiliza&ccedil;&atilde;o de grandes volumes correntes foi associado com uma maior convers&atilde;o da forma de grandes agregados (ativa) em pequenos agregados (inativa)<sup>(14,15,24,27)</sup>. </P>     <P ALIGN="JUSTIFY">Nossos objetivos neste estudo foram os seguintes: a) avaliar o efeito na oxigena&ccedil;&atilde;o e ventila&ccedil;&atilde;o de coelhos artificialmente depletados de surfactante quando submetidos &agrave; ventila&ccedil;&atilde;o mec&acirc;nica convencional, usando um volume corrente de 10 ml/kg e PEEP de 5cm H2O associado com uma reposi&ccedil;&atilde;o parcial de surfactante ex&oacute;geno; b) comparar a evolu&ccedil;&atilde;o desse grupo com outro grupo submetido &agrave; ventila&ccedil;&atilde;o de alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o (HFO) sem reposi&ccedil;&atilde;o associada de surfactante.</P> <B></B></FONT>     <P ALIGN="JUSTIFY"><font size="3" face="Verdana"><b>    <br>   M&eacute;todos </b></font></P> <FONT FACE="Verdana" SIZE=2>     <P ALIGN="JUSTIFY">O presente estudo foi realizado de acordo com as normas do National Institute of Health: guidelines for use of experimental animals (Canada) e com a aprova&ccedil;&atilde;o do Institutional Animal Care and Use Committee (Canada). </P> </FONT>    <P ALIGN="JUSTIFY"><font size="2" face="Verdana">Vinte coelhos brancos da ra&ccedil;a New Zealand, pesando aproximadamente 3kg foram pr&eacute;-medicados com acepromazine (0,5mg/kg intramuscular) e anestesiados com pentobarbital s&oacute;dico (10-20mg/kg intravenoso). Um acesso venoso perif&eacute;rico foi estabelecido para infus&atilde;o de fluidos e inserida uma linha arterial na art&eacute;ria auricular para monitoriza&ccedil;&atilde;o hemodin&acirc;mica cont&iacute;nua (Hewlett-Packard pressure transducer model 1280), assim como, permitir coletas seriadas de sangue para gasometria arterial (Radiometer ABL 3300). Um tubo endotraqueal com di&acirc;metro 3,5 mm ou 4,0 mm foi inserido via traqueostomia. Anestesia e paralisia muscular foram obtidas atrav&eacute;s de uma infus&atilde;o cont&iacute;nua de pentobarbital (6mg/kg/h) e pancur&ocirc;nio (0,2mg/kg/h). A manuten&ccedil;&atilde;o h&iacute;drica foi de 7 ml/kg/hora de uma solu&ccedil;&atilde;o salina (NaCl a 0,9%) adicionada com glicose a 5%. A satura&ccedil;&atilde;o da hemoglobina foi monitorizada continuamente (Nellcor) e a temperatura corporal foi monitorizada e mantida constante (entre 38 e 39 &deg;C) com uso de uma fonte de calor irradiante e cobertor t&eacute;rmico. O volume corrente foi monitorizado atrav&eacute;s de um monitor (thermistor pneumotachograph - BEAR NVM-1, BEAR medical Systems, Riverside, CA) com reduzido espa&ccedil;o morto (1,3ml), inserido entre o tubo traqueal e o circuito do respirador. </font></P> <FONT FACE="Verdana" SIZE=2>    ]]></body>
<body><![CDATA[<P ALIGN="JUSTIFY"><I><strong>Interven&ccedil;&atilde;o:</strong></i> Imediatamente ap&oacute;s a realiza&ccedil;&atilde;o da traqueostomia os animais foram ventilados no modo de press&atilde;o controlada objetivando um volume corrente de 10ml/ kg, com uma PEEP de 0cm H<sub>2</sub>O, uma FiO2 de 100%, uma freq&uuml;&ecirc;ncia respirat&oacute;ria de 30 ventila&ccedil;&otilde;es por minuto, e um tempo inspirat&oacute;rio de 0,65 s. (Humming V, Senko Medical Instruments, Tokyo, Japan). Os animais foram mantidos com este regime por um per&iacute;odo de 30 minutos (controle). </P>     <P ALIGN="JUSTIFY">Posteriormente, os coelhos foram artificialmente induzidos &agrave; deple&ccedil;&atilde;o de surfactante end&oacute;geno atrav&eacute;s de sucessivas lavagens pulmonares com al&iacute;quotas (25 ml/kg) de solu&ccedil;&atilde;o fisiol&oacute;gica aquecida, administradas atrav&eacute;s do tubo traqueal. </P>     <P ALIGN="JUSTIFY">Concomitantemente o t&oacute;rax dos animais era gentilmente massageado para melhor distribui&ccedil;&atilde;o do fluido dentro dos pulm&otilde;es. T&atilde;o logo se observasse uma queda acentuada na press&atilde;o arterial, na freq&uuml;&ecirc;ncia card&iacute;aca ou na satura&ccedil;&atilde;o da hemoglobina, o l&iacute;quido infundido nos pulm&otilde;es era succionado. </P>     <P ALIGN="JUSTIFY">A monobra era repetida (usualmente entre 4 e 6 vezes) at&eacute; atingir uma satura&ccedil;&atilde;o da hemoglobina inferior a 90% e uma PaO<sub>2</sub> menor que 100 mmHg com uma FiO<sub>2</sub> de 100%, PEEP de 5 cmH<sub>2</sub>O; freq&uuml;&ecirc;ncia respirat&oacute;ria de 30 mpm, tempo inspirat&oacute;rio de 0,65 segundos e pico de press&atilde;o inspirat&oacute;ria (PIP) necess&aacute;rio para atingir um volume corrente de 10 ml/kg. </P>     <P ALIGN="JUSTIFY">De acordo com a estrat&eacute;gia ventilat&oacute;ria a ser adotada, os animais eram divididos em dois grupos principais: a) ventila&ccedil;&atilde;o convencional associada com reposi&ccedil;&atilde;o parcial de surfactante ex&oacute;geno (CMV+S); b) ventila&ccedil;&atilde;o de alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o (HFO). Dentro de cada grupo havia animais com discretas diferen&ccedil;as no tratamento utilizado, relacionados a outros experimentos associados. Conseq&uuml;entemente, quatro diferentes subgrupos puderam ser identificados: </P>     <P ALIGN="JUSTIFY">a) ventila&ccedil;&atilde;o convencional associada com reposi&ccedil;&atilde;o parcial de surfactante ex&oacute;geno (CMV+S): oito coelhos foram submetidos &agrave; ventila&ccedil;&atilde;o mec&acirc;nica convencional com os seguintes par&acirc;metros: FiO<sub>2</sub>de 1,0; PEEP de 5 cmH<sub>2</sub>O; freq&uuml;&ecirc;ncia respirat&oacute;ria de 30 mpm; tempo inspirat&oacute;rio de 0,65 segundos e PIP necess&aacute;ria para obter um volume corrente de 10 ml/kg. Esses par&acirc;metros foram fixados antes da administra&ccedil;&atilde;o do surfactante ex&oacute;geno e permaneceram fixos durante todo o per&iacute;odo de estudo. De acordo com o regime de surfactante utilizado os coelhos poderiam pertencer a dois subgrupos: </P>     <P ALIGN="JUSTIFY">a1) CMV+Sa: quando a ventila&ccedil;&atilde;o convencional era associada apenas a uma reposi&ccedil;&atilde;o parcial de surfactante ex&oacute;geno. Houve quatro coelhos (peso m&eacute;dio de 2,99 +0,10 kg) que receberam extrato de surfactante bovino (27 mg/ml) na dose de 1 ml/kg imediatamente ap&oacute;s os par&acirc;metros da ventila&ccedil;&atilde;o terem sido atingidos e fixados. </P>     <P ALIGN="JUSTIFY">a2) CMV+Sd: quando a ventila&ccedil;&atilde;o convencional era associada a uma reposi&ccedil;&atilde;o parcial de surfactante ex&oacute;geno associado com Dextran. Houve quatro coelhos (peso m&eacute;dio de 3,00 +0,14 kg) que receberam extrato de surfactante bovino (27 mg/ml) na dose de 1 ml/kg associados com 2 ml de Dextran (peso mol&eacute;cula de 70.000) na concentra&ccedil;&atilde;o de 50mg/ml. O Dextran foi associado para explorar a possibilidade de aumento da atividade do surfactante conforme demonstrado em alguns estudos in vitro28,29. O extrato de surfactante bovino e o Dextram somente foram administrados ap&oacute;s os par&acirc;metros da ventila&ccedil;&atilde;o mec&acirc;nica convencional terem sido atingidos e fixados. </P>     <P ALIGN="JUSTIFY">b) ventila&ccedil;&atilde;o de alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o (HFO) sem administra&ccedil;&atilde;o de surfactante ex&oacute;geno. Dependendo da freq&uuml;&ecirc;ncia respirat&oacute;ria utilizada, os 12 coelhos deste grupo foram divididos em dois subgrupos: </P>     <P ALIGN="JUSTIFY">b1) HFO15 &shy; ventila&ccedil;&atilde;o por oscila&ccedil;&atilde;o com 15 Hz de freq&uuml;&ecirc;ncia, utilizada em seis coelhos (peso m&eacute;dio de 3.03 +015 Kg), com uma press&atilde;o m&eacute;dia de vias a&eacute;reas (MAP) de 15 cmH<sub>2</sub>O, tempo inspirat&oacute;rio de 33%, FiO2 100%. A amplitude e o power foram ajustados para manter uma pCO2 ao redor de 40 mmHg. </P>     ]]></body>
<body><![CDATA[<P ALIGN="JUSTIFY">b2) HFO5 &shy; ventila&ccedil;&atilde;o por oscila&ccedil;&atilde;o com 5 Hz de freq&uuml;&ecirc;ncia, utilizada em seis coelhos (peso m&eacute;dio de 2.93+0.22 kg), com uma press&atilde;o m&eacute;dia de vias a&eacute;reas (MAP) de 15 cmH2O, tempo inspirat&oacute;rio de 33%, FiO<sub>2</sub> 100%. A amplitude e o power foram ajustados para manter uma pCO<sub>2</sub> ao redor de 40 mmHg. </P>     <P ALIGN="JUSTIFY">Avalia&ccedil;&otilde;es: gasometrias arteriais eram coletadas em cinco momentos distintos: antes da lavagem pulmonar (controle), ap&oacute;s a lavagem pulmonar, 15 minutos, 60 minutos e 120 minutos ap&oacute;s iniciado o tratamento. Os dois grupos principais (CMV+S versus HFO) e os quatro subgrupos (CMV+Sa, CMV+Sd, HFO15, HFO5) foram avaliados e comparados baseados em suas diferen&ccedil;as no paO<sub>2</sub>, pH, PCO<sub>2</sub>, &iacute;ndice de oxigena&ccedil;&atilde;o [(FiO<sub>2</sub> x MAP / PaO<sub>2</sub>)x 100] e press&atilde;o arterial m&eacute;dia nestes cinco momentos de observa&ccedil;&atilde;o. </P>     <P ALIGN="JUSTIFY">Os dados cont&iacute;nuos foram expressos atrav&eacute;s de m&eacute;dias e de seus desvios padr&atilde;o (DP). As m&eacute;dias dos dois grupos principais (HFO versus CMV+S) foram comparadas utilizando o teste t de Student, enquanto que a Anova de uma via foi utilizada para comparar as m&eacute;dias de cada vari&aacute;vel entre os quatro subgrupos (CMV+Sa, CMV+Sd, HFO15 e HFO5). </P>     <P ALIGN="JUSTIFY">Um valor de "p" inferior a 0,05 foi considerado como diferen&ccedil;a significativa.</P> <B></B></FONT>     <P ALIGN="JUSTIFY"><font size="3" face="Verdana"><b>    <br>   Resultados </b></font></P> <FONT FACE="Verdana" SIZE=2>     <P ALIGN="JUSTIFY">Durante o per&iacute;odo "controle" (pr&eacute; lavagem pulmonar), os quatro subgrupos n&atilde;o apresentaram nenhuma diferen&ccedil;a no que se refere ao peso m&eacute;dio dos coelhos ou n&uacute;mero de lavagens pulmonares, assim como as PaO2, PaCO2, e pH m&eacute;dios dos quatro subgrupos n&atilde;o diferiram (Anova de uma via) antes da lavagem pulmonar. Da mesma forma, durante os demais quatro momentos de avalia&ccedil;&atilde;o do estudo (p&oacute;s lavagem pulmonar, 15, 60 e 120 minutos p&oacute;s tratamento) encontramos os mesmos e consistentes resultados quando comparamos os quatro subgrupos (CMV+Sa, CMV+Sd, HFO15 e HFO5, atrav&eacute;s da Anova de uma via) ou quando os dois grupos principais foram comparados (HFO e CMV+S, atrav&eacute;s do teste t de Student). Assim, por raz&otilde;es pr&aacute;ticas, os resultados deste estudo ser&atilde;o apresentados (<a href="#t1">Tabela 1</a>), agrupando os quatro subgrupos nos dois grupos principais: HFO (HFO15 mais HFO5) versus CMV+S (CMV+Sa mais CMV+Sd).</P>     <P ALIGN="center"><a name="t1"></a><img src="/img/revistas/rbp/v41n3/tabla11_1.gif" width="317" height="546"></P>     <P ALIGN="JUSTIFY">Ap&oacute;s a lavagem pulmonar, a PaO2 m&eacute;dia no grupo submetido &agrave; ventila&ccedil;&atilde;o convencional associada &agrave; reposi&ccedil;&atilde;o de surfactante (CMV+S) foi de 43,6 &plusmn; 9,9 mmHg sem apresentar diferen&ccedil;a (p=0,154) quando comparado com os coelhos submetidos &agrave; ventila&ccedil;&atilde;o de alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o ou grupo HFO (50,7 &plusmn;10,9 mmHg). Ap&oacute;s 15 minutos de tratamento, observouse um importante aumento na PaO2 m&eacute;dia em ambos grupos. A PaO2 m&eacute;dia aos 15 minutos nos coelhos alocados para CMV+S aumentou para 254,2 &plusmn; 107,7 mmHg, enquanto que no grupo HFO atingiu a 288,5 &plusmn; 173,6 mmHg, sem apresentar diferen&ccedil;a (p=0,626). Entretanto, ap&oacute;s 1 e 2 horas de tratamento (<a href="#f1">Figura 1</a>, <a href="#t1">Tabela 1</a>), o grupo HFO apresentou valores de PaO2 muito mais elevados (431,8 &plusmn; 65,4 mmHg e 431,4 &plusmn; 72,4 mmHg, respectivamente) quando comparado (p&lt;0,001) com o grupo CMV+S (148,8 &plusmn; 101,6 mmHg e 126,1 &plusmn; 88,1 mmHg, respectivamente).</P> </FONT>     <P ALIGN="CENTER"><a name="f1"></a><img src="/img/revistas/rbp/v41n3/figura11_1.gif" width="324" height="229"></P> <FONT FACE="Verdana" SIZE=2>     ]]></body>
<body><![CDATA[<P ALIGN="JUSTIFY">N&atilde;o observamos nenhuma diferen&ccedil;a nos &iacute;ndices de oxigena&ccedil;&atilde;o entre os dois grupos ap&oacute;s a lavagem pulmonar (p=0,166) e ap&oacute;s 15 minutos de estudo (p=0,187). Entretanto, ap&oacute;s 60 minutos e 120 minutos (<a href="#f2">Figura 2</a> e <a href="#t1">Tabela 1</a>), o &iacute;ndice de oxigena&ccedil;&atilde;o no grupo submetido &agrave; ventila&ccedil;&atilde;o de alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o era menor (3,6 &plusmn; 0,6 e 3,4 &plusmn; 0,8; respectivamente) quando comparado (p&lt;0,001) com aqueles coelhos que utilizaram CMV+S (10,3 &plusmn; 6,1; 12,3 &plusmn; 3,4; respectivamente).</P>     <P ALIGN="CENTER"> <a name="f2"></a><img src="/img/revistas/rbp/v41n3/figura11_2.gif" width="321" height="219"></P>     <P ALIGN="JUSTIFY">Em ambos os grupos, ap&oacute;s a lavagem pulmonar, a press&atilde;o m&eacute;dia nas vias a&eacute;reas (MAP) era a mesma (p=0,980). Entretanto, aos 15, 60 e 120 minutos ap&oacute;s serem alocados para HFO ou CMV+S, observou-se que o grupo CMV+S apresentou uma MAP significativamente menor (p&lt;0,001) que o grupo HFO (<a href="#t1">Tabela 1</a> e <a href="#f3">Figura 3</a>).</P>     <P ALIGN="CENTER"> <a name="f3"></a><img src="/img/revistas/rbp/v41n3/figura11_3.gif" width="325" height="241"></P>     <P ALIGN="JUSTIFY">No per&iacute;odo p&oacute;s lavagem pulmonar, n&atilde;o observamos nenhuma diferen&ccedil;a entre os dois grupos nos n&iacute;veis de PaCO2 (p=0,508). Por&eacute;m, ap&oacute;s uma hora de estudo (<a href="#t1">Tabela 1</a> e <a href="#f4">Figura 4</a>) o grupo submetido a CMS+S apresentava uma PaCO2 m&eacute;dia (29,0 +5.4 mmHg) significativamente menor (p=0,008) que os coelhos submetidos a HFO (41.5 +12.6 mmHg).</P>     <P ALIGN="CENTER"> <a name="f4"></a><img src="/img/revistas/rbp/v41n3/figura11_4.gif" width="327" height="225"></P>     <P ALIGN="JUSTIFY">Ap&oacute;s uma hora de tratamento os coelhos pertencentes ao grupo CMV+S apresentaram press&otilde;es arteriais m&eacute;dias de 55,6 +11,1mmHg, que era significativamente menor (p=0,026) que os n&iacute;veis press&oacute;ricos apresentados pelo grupo HFO (71,8 +18,5mmHg). Durante os demais per&iacute;odos de observa&ccedil;&atilde;o n&atilde;o encontramos nenhuma diferen&ccedil;a estat&iacute;stica quando os n&iacute;veis press&oacute;ricos arteriais dos dois grupos foram comparados (<a href="#t1">Tabela 1</a> e <a href="#f5">Figura 5</a>).</P>     <P ALIGN="CENTER"> <a name="f5"></a><img src="/img/revistas/rbp/v41n3/figura11_5.gif" width="326" height="238"></P>     <P ALIGN="JUSTIFY">Durante os cinco momentos de observa&ccedil;&atilde;o do presente estudo, n&atilde;o observamos nenhuma diferen&ccedil;a quando os pH arteriais dos dois grupos foram comparados (<a href="#t1">Tabela 1</a>).</P> <B></B></FONT>     <P ALIGN="JUSTIFY"><font size="3" face="Verdana"><b>    ]]></body>
<body><![CDATA[<br>   Discuss&atilde;o</b></font></P> <FONT FACE="Verdana" SIZE=2>     <P ALIGN="JUSTIFY">Neste estudo, envolvendo coelhos induzidos &agrave; deple&ccedil;&atilde;o pulmonar de surfactante e posteriormente submetidos a duas estrat&eacute;gias diferentes de tratamento, foi poss&iacute;vel demonstrar (a) que a utiliza&ccedil;&atilde;o de uma estrat&eacute;gia ventilat&oacute;ria n&atilde;o protetora associada &agrave; reposi&ccedil;&atilde;o de surfactante, promoveu um imediato aumento (15 min) na oxigena&ccedil;&atilde;o. Entretanto este efeito foi r&aacute;pida e progressivamente dissipado durante os pr&oacute;ximos 120 minutos; (b) que a utiliza&ccedil;&atilde;o de uma estrat&eacute;gia alternativa de ventila&ccedil;&atilde;o protetora (HFO Ventila&ccedil;&atilde;o de alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o)) mesmo que n&atilde;o associada com a reposi&ccedil;&atilde;o de surfactante promoveu uma r&aacute;pida (15min) e persistente (60 e 120 minutos) melhora na oxigena&ccedil;&atilde;o, e com n&iacute;veis superiores aos obtidos pelos animais submetidos &agrave; ventila&ccedil;&atilde;o mec&acirc;nica convencional (n&atilde;o protetora) associada com reposi&ccedil;&atilde;o de surfactante durante as duas horas de observa&ccedil;&atilde;o. </P>     <P ALIGN="JUSTIFY">Antes de discutirmos esses resultados, julgamos pertinente que alguns detalhes do experimento sejam considerados: Defini&ccedil;&atilde;o da dose do surfactante utilizado: a dose estimada para repor todo o reservat&oacute;rio pulmonar de surfactante situa-se ao redor de 100 mg/kg<sup>(24,27)</sup>. Estudos similares em animais t&ecirc;m utilizado uma dose entre 50 a 100 mg/ kg<sup>(14,15,24-26)</sup>. Dentro de boas condi&ccedil;&otilde;es o surfactante ex&oacute;geno tem uma meia vida estimada em torno de 5 horas<sup>(24,27)</sup>. </P>     <P ALIGN="JUSTIFY">Entretanto, dependendo da prepara&ccedil;&atilde;o utilizada, do m&eacute;todo de administra&ccedil;&atilde;o, do curso da doen&ccedil;a, da presen&ccedil;a de inibidores e da estrat&eacute;gia ventilat&oacute;ria utilizada, a meia vida do surfactante ex&oacute;geno administrado pode ser significativamente reduzida<sup>(3,10,12,14,15,23)</sup>. Assim, optamos por utilizar aquela considerada como a menor dose efetiva de surfactante (27 mg/kg), obtida atrav&eacute;s de estudos pr&eacute;vios em nosso laborat&oacute;rio. Ao analisarmos os dados de nossa pesquisa, constatase que ap&oacute;s 15 minutos da administra&ccedil;&atilde;o de surfactante ocorreu um grande aumento na PaO2 (de 43,6 para 254,2 mmHg), e melhora no &iacute;ndice de oxigena&ccedil;&atilde;o (de 26,8 para 4,96), demonstrando que a dose administrada, apesar de reduzida, era realmente efetiva. Entretanto, a escolha de uma dose m&iacute;nima efetiva nos permite demonstrar de forma mais evidente o efeito da ventila&ccedil;&atilde;o convencional sobre a atividade do surfactante ex&oacute;geno administrado. </P>     <P ALIGN="JUSTIFY">No caso desta forma de ventila&ccedil;&atilde;o ser protetora ou sin&eacute;rgica com a a&ccedil;&atilde;o do surfactante, o seu efeito sobre a oxigena&ccedil;&atilde;o seria mantido por um longo per&iacute;odo. Por outro lado, na eventualidade de atuar como um agente inibidor, o efeito sobre a oxigena&ccedil;&atilde;o rapidamente seria perdido. </P>     <P ALIGN="JUSTIFY">Por que um subgrupo recebeu Dextram associado ao surfactante? Existem alguns experimentos in vitro que demonstraram que o dextram al&eacute;m de apresentar um efeito protetor, potencializaria a a&ccedil;&atilde;o do surfactante<sup>(28,29)</sup>. Alguns dos animais de nosso experimento pertenciam tamb&eacute;m a este estudo em paralelo que pretendia avaliar esta possibilidade in vivo. Entretanto, como ambos subgrupos (surfactante isolado e surfactante associado ao dextram) no presente estudo apresentaram o mesmo comportamento, decidimos consider&aacute;-los como um &uacute;nico grupo. </P>     <P ALIGN="JUSTIFY">Por que n&atilde;o utilizar PEEP mais elevado? Resultados de experimentos anteriores, utilizando este mesmo modelo animal, demonstraram que, aplicando-se um PEEP acima de 9 cmH2O, apresentavam uma mortalidade de 100%,1,5 hora ap&oacute;s haver sido administrado o surfactante. Por outro lado, a utiliza&ccedil;&atilde;o de um PEEP em torno de 5cm H2O demonstrou ser efetivo, seguro e com o efeito mais prolongado sobre a oxigena&ccedil;&atilde;o. Sendo esta a raz&atilde;o de nossa escolha<sup>(10,12,23,30)</sup>.</P>     <P ALIGN="JUSTIFY">Em um primeiro momento (15 minutos), tanto o grupo de coelhos submetidos &agrave; ventila&ccedil;&atilde;o convencional (n&atilde;o protetora) associada &agrave; administra&ccedil;&atilde;o de surfactante como aqueles coelhos submetidos &agrave; ventila&ccedil;&atilde;o de alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o apresentam os mesmo efeitos na oxigena&ccedil;&atilde;o. </P>     <P ALIGN="JUSTIFY">Paralelo a este efeito, deve-se ressaltar a acentuada queda na PaCO2 (aumento do volume minuto) no grupo que recebeu surfactante. Como os par&acirc;metros do respirador eram mantidos fixos (freq&uuml;&ecirc;ncia respirat&oacute;ria e press&atilde;o inspirat&oacute;ria), imagina-se que, ap&oacute;s a administra&ccedil;&atilde;o de surfactante, &aacute;reas anteriormente colapsadas voltaram a ser ventiladas, contribuindo para o aumento verificado no volume minuto. Por&eacute;m, aos 60 e 120 minutos, ainda sem modificar os par&acirc;metros do respirador, observase neste grupo que recebeu surfactante, um aumento da PaCO2 associado a uma diminui&ccedil;&atilde;o progressiva da PaO2. Seguindo esta linha de racioc&iacute;nio, imaginase que neste momento, tenha havido uma progressiva diminui&ccedil;&atilde;o da &aacute;rea de trocas pulmonares, provavelmente por colapso progressivo das unidades alveolares. </P>     <P ALIGN="JUSTIFY">Na SARA, o colapso pulmonar progressivo durante a ventila&ccedil;&atilde;o mec&acirc;nica tem sido associado a a) uso de PEEP insuficiente, permitindo a redu&ccedil;&atilde;o do volume alveolar no final da expira&ccedil;&atilde;o (atelectrauma); b) uso de altos volumes correntes levando &agrave; hiperdistens&atilde;o alveolar (volutrauma), distens&atilde;o do tecido alveolar com processo inflamat&oacute;rio local (biotrauma) e progressiva inativa&ccedil;&atilde;o do surfactante<sup>(2-6,10,23)</sup>.</P>     ]]></body>
<body><![CDATA[<P ALIGN="JUSTIFY">Desde que optamos por utilizar n&iacute;veis de PEEP considerados adequados e protetores neste modelo animal<sup>(10,12,23,30)</sup>, acreditamos que o colapso pulmonar progressivo seja prioritariamente conseq&uuml;&ecirc;ncia de volutrauma e biotrauma<sup>(2-4)</sup>. </P>     <P ALIGN="JUSTIFY">Nestes dois tipos de les&atilde;o induzida pela ventila&ccedil;&atilde;o mec&acirc;nica, o volume corrente elevado (neste caso 10 ml/kg), apresentase como o principal agente causador<sup>(2-4,10)</sup>. O poder iatrog&ecirc;nico do volume corrente elevado como indutor de les&atilde;o pulmonar em nosso estudo foi t&atilde;o pronunciado e extremamente r&aacute;pido que neutralizou os benef&iacute;cios obtidos com a reposi&ccedil;&atilde;o de surfactante em um per&iacute;odo inferior a 60 minutos. </P>     <P ALIGN="JUSTIFY">Por outro lado, a utiliza&ccedil;&atilde;o de uma t&eacute;cnica ventilat&oacute;ria n&atilde;o convencional (HFO), baseada em baix&iacute;ssimos volumes correntes administrados em altas freq&uuml;&ecirc;ncias respirat&oacute;rias (5 e 15 Hz), permitiu uma eleva&ccedil;&atilde;o imediata na oxigena&ccedil;&atilde;o e mantida no mesmo patamar durante as duas horas do experimento. Chama a aten&ccedil;&atilde;o neste experimento utilizando coelhos deprivados de surfactante que j&aacute; na 1 hora de uso da ventila&ccedil;&atilde;o de alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o (HFO) mostrouse ser muito mais eficaz na melhora da oxigena&ccedil;&atilde;o do que utiliza&ccedil;&atilde;o surfactante associada &agrave; ventila&ccedil;&atilde;o convencional. </P>     <P ALIGN="JUSTIFY">Apesar de n&atilde;o constar dos objetivos do presente estudo, cabe ressaltar que a melhora na oxigena&ccedil;&atilde;o permaneceu inalterada at&eacute; completar seis horas de observa&ccedil;&atilde;o (<a href="#f1">Figura 1</a>), quando foi interrompida a avalia&ccedil;&atilde;o (dados referentes a outro experimento). </P>     <P ALIGN="JUSTIFY">A ventila&ccedil;&atilde;o de alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o, tem apresentado resultados consistentes em animais de laborat&oacute;rio induzidos a SARA<sup>(11,17,20,31)</sup>. Os benef&iacute;cios da HFO na SARA poderiam ser atribu&iacute;dos a dois fatores: a manuten&ccedil;&atilde;o de uma press&atilde;o constante nas vias a&eacute;reas e o uso de diminutos volumes correntes<sup>(11,17,20,31)</sup>. Esses dois fatores t&ecirc;m como principais vantagens evitar o colapso pulmonar progressivo (mant&ecirc;m a estabilidade alveolar), evitar grandes oscila&ccedil;&otilde;es no volume alveolar (previnem a distens&atilde;o e o colapso alveolar), poupar surfactante e diminuir o processo inflamat&oacute;rio local<sup>(2,5,6,11,13,18,20,21,31)</sup>.</P>     <P ALIGN="JUSTIFY">Ao contr&aacute;rio da Doen&ccedil;a de Membrana Hialina do rec&eacute;mnascido, a SARA &eacute; uma doen&ccedil;a multifatorial em que a defici&ecirc;ncia de surfactante &eacute; apenas um dos m&uacute;ltiplos aspectos desta S&iacute;ndrome<sup>(1,2,24,25)</sup>. Por esta raz&atilde;o, o melhor planejamento terap&ecirc;utico deve ser baseado em um conjunto de a&ccedil;&otilde;es utilizando os potenciais benef&iacute;cios de cada uma destas a&ccedil;&otilde;es. Dentro deste conceito, tem sido extensivamente demonstrado que o uso de ventila&ccedil;&atilde;o mec&acirc;nica protetora em pacientes com SARA reduz a incid&ecirc;ncia de les&atilde;o pulmonar induzida pela ventila&ccedil;&atilde;o mec&acirc;nica, assim como aumenta a significativamente a sobrevida<sup>(8,9)</sup>. Neste aspecto, a ventila&ccedil;&atilde;o de alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o (HFO) parece preencher adequadamente os crit&eacute;rios de seguran&ccedil;a e efic&aacute;cia pretendidos com a ventila&ccedil;&atilde;o pulmonar protetora, constituindose em uma excelente op&ccedil;&atilde;o terap&ecirc;utica.</P> <B></B></FONT>     <P ALIGN="JUSTIFY"><font size="3" face="Verdana"><b>    <br>   Refer&ecirc;ncias bibliogr&aacute;ficas</b></font></P> <FONT FACE="Verdana" SIZE=2>     <P ALIGN="JUSTIFY">1. Piva JP, Garcia PC, Carvalho PR, Luchese S. S&iacute;ndrome do desconforto (ang&uacute;stia) respirat&oacute;rio agudo (SDRA/SARA). In: Piva J, Carvalho P, Garcia PC, eds. Terapia Intensiva em Pediatria. 4a edi&ccedil;&atilde;o. Rio de Janeiro: Medsi; 1997. p.176-96. </P>     <!-- ref --><P ALIGN="JUSTIFY">2. Slutzky AS. Lung injury caused by mechanical ventilation. Chest 1999; 116:9S-15S. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433340&pid=S1024-0675200200030001100002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">3. Hudson LD. Progress in understanding ventilator-induced lung injury. JAMA 1999;282:77-8. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433341&pid=S1024-0675200200030001100003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">4. Ranieri VM, Slutzky AS. Respiratory physiology and acute lung injury: the miracle of lazarus. Intesive Care Medicine 1999; 25: 1040-3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433342&pid=S1024-0675200200030001100004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">5. Clark RH, Slutsky AS, Gerstmann DR. Lung protective strategies of ventilation in the neonate: what are they? Pediatrics 2000; 105:112-4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433343&pid=S1024-0675200200030001100005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">6. Dreyfuss D, Saumon G. Ventilator-induced lung injury. Am J Respir Crit Care Med 1998; 157: 294-323. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433344&pid=S1024-0675200200030001100006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">7. Creamer KM, McCloud LL, Fisher LE, Ehrhart I. Closing pressure rather than opening pressure determines optimal positive end expiratory pressure and avoids overdistention. Chest 1999; 116:26s-27s. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433345&pid=S1024-0675200200030001100007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">8. Amato MB, Barbas CS, Medeiros DM. Effect of a protectiveventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998; 338: 347-54. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433346&pid=S1024-0675200200030001100008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">9. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-8. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433347&pid=S1024-0675200200030001100009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">10. Taskar V, John J, Evander E, Robertson B, Jonson B. Surfactant dysfunction makes lungs vulnerable to repetitive collapse and reexpansion. Am J Respir Crit Care Med 1997; 155: 313-20. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433348&pid=S1024-0675200200030001100010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">11. Kolton M, Cattran CB, Kent G, Volgyesi G, Froese AB, Bryan AC. Oxygenation during high-frequency ventilation compared with conventional mechanical ventilation in two models of lung injury. Anesth Analg 1982; 61: 323-32. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433349&pid=S1024-0675200200030001100011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">12. Froese AB, McCulloch PR, Sugiura M, Vaclavik S, Possmayer F, Moller F. Optimizing alveolar expansion prolongs the effectiveness of exogenous surfactant therapy in the adult rabbit Am Rev Respir Dis 1993;148:569-77. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433350&pid=S1024-0675200200030001100012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">13. Doctor A, Arnold J. Mechanical support of acute lung injury: options for strategic ventilation. New Horizons 1999; 7: 359-73. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433351&pid=S1024-0675200200030001100013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">14. Ito Y, Manwell SEE, Kerr CL, Veldhuizen RAW, Yao LJ, Bjarneson D et al. Effects of ventilation strategies on efficacy of exogenous surfactante therapy in a rabbit model lung injury. Am J Respir Crit Care Med 1997; 157: 149-55. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433352&pid=S1024-0675200200030001100014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">15. Ito Y, Veldhuizen RAW, Yao LJ, McCaig A, Barttlett AJ, Lewis JF et al. Ventilation strategies affect surfactant aggregate conversion in acute lung injury. Am J Respir Crit Care Med 1997; 155: 493-9. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433353&pid=S1024-0675200200030001100015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">16. Hatcher D. Watanabe H, Ashbury T, Vincent S, Fisher J, Froese A. Mechanical performance of clinically available neonatal, high-frequency, oscilatory-type ventilators. Crit Care Med 1998; 26:1081-88. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433354&pid=S1024-0675200200030001100016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">17. McCulloch, PR, Forkert, PG, Froese, AB. Lung volume maintenance prevents lung injury during high frequency oscillation in surfactant deficient rabbits. Am Rev Respir Dis 1988; 137, 1185-92. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433355&pid=S1024-0675200200030001100017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">18. Thome U, T&ouml;pfer A, Achaller P, Pohlandt F. Effect of mean airway pressure on lung volume during high-frequency oscillatory ventilation of preterm infants. Am J Respir Crit Care Med 1998; 157:1213-18. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433356&pid=S1024-0675200200030001100018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">19. Meredith KS, de Lemos RA, Coalson JJ. Role of lung injury in pathogenesis of hyaline membrane disease in premature baboons. J Appl Physiol 1989; 66: 2150-8. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433357&pid=S1024-0675200200030001100019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">20. Hamilton, PP, Onayemi A, Smyth JA, Gillan JE, Cutz E, Froese AB et al. Comparison of conventional and high-frequency ventilation: oxygenation and lung pathology. J Appl Physiol 1983; 55: 131-8. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433358&pid=S1024-0675200200030001100020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">21. Takata M, Abe J, Tanaka H, Kitano Y, Doi Z, Koshaka T et al. Intra-alveolar expression of tumor necrosis factor gene during conventional and high frequency ventilation. Am J Respir Crit Care Med 1997; 156: 272-9. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433359&pid=S1024-0675200200030001100021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">22. Cochrane CG, Revak SD. Surfactant lavage treatment in a model of respiratory distress syndrome. Chest 1999; 116:85s-87s. 356 Jornal de Pediatria - Vol. 76, N5, 2000 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433360&pid=S1024-0675200200030001100022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">23. Kerr CL, Ito Y, Manwell SEE, Veldhuizen RAW, Yao LJ, McCaig LA, Lewis JF. Effects of surfactant distribution and ventilation strategies on efficacy of exogenous surfactant. J Appl Physiol 1998; 85: 676-84. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433361&pid=S1024-0675200200030001100023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">24. Bauman LA, Willson DF. Surfactant in pediatric respiratory failure. New Horizons 1999; 7: 399-413. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433362&pid=S1024-0675200200030001100024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">25. Gregory TJ, Steinberg KP, Spragg R. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155: 1309-15. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433363&pid=S1024-0675200200030001100025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">26. Kruse MF, Sch&uuml;lt-M&ouml;nting J, Hoehn T. Rate of surfactant administration influences lung function and gas exchange in a surfactant-deficient rabbit model. Pediatr Pulmonol 1998; 25: 196-204. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433364&pid=S1024-0675200200030001100026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">27. Hills BA. An alternative view of the role of surfactant and the alveolar model. J Appl Physiol 1999; 87:1567-83. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433365&pid=S1024-0675200200030001100027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">28. Kobayashi T, Ohta K, Tashiro K, Nishizuka K, Chen W, Ohmura S et al. Dextran restores albumin-inhibited surface activity of pulmonary surfactant extract. J Appl Physiol 1999; 86: 1778-84. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433366&pid=S1024-0675200200030001100028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">29. Tauesch HW, Lu KW, Goerke J, Clements JA. Nonionic polymers reverse inactivation of surfactant by meconium and other substances. Am J Respir Crit Care Med 1999; 159: 1391-5. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433367&pid=S1024-0675200200030001100029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">30. Sohma, A, Brampton, WJ, Dunnill, MS. Effect of ventilation with positive end-expiratory pressure on the development of lung damage in experimental acid aspiration pneumonia in the rabbit. Intensive Care Med 1992; 18,112-7. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433368&pid=S1024-0675200200030001100030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><P ALIGN="JUSTIFY">31. Chang HK. Mechanisms of gas transport during ventilation by high frequency oscillation. J Appl Physiol 1984: 56: 553-63.Ventila&ccedil;&atilde;o de alta freq&uuml;&ecirc;ncia por oscila&ccedil;&atilde;o comparada... - Piva JP et al&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=433369&pid=S1024-0675200200030001100031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p align="justify"><font size="2" face="Verdana"><strong><font size="1">Endere&ccedil;o para correspond&ecirc;ncia:</font></strong><font size="1"> Dr. Jefferson P. Piva Hospital S&atilde;o Lucas da PUCRS - UTI Av. Ipiranga 6690 - 5 andar CEP 91610-000 - Porto Alegre - RS - Brasil Fone/fax: (51) 315.2400 &shy; E-mail: <a href="mailto:jpiva@pucrs.br">jpiva@pucrs.br</a></font></font></p>     ]]></body>
<body><![CDATA[ ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piva]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Luchese]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Síndrome do desconforto (angústia) respiratório agudo (SDRA/SARA)]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Piva]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
</person-group>
<source><![CDATA[Terapia Intensiva em Pediatria]]></source>
<year>1997</year>
<edition>4a</edition>
<page-range>176-96</page-range><publisher-loc><![CDATA[Rio de Janeiro ]]></publisher-loc>
<publisher-name><![CDATA[Medsi]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Slutzky]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Lung injury caused by mechanical ventilation]]></article-title>
<source><![CDATA[Chest]]></source>
<year>1999</year>
<volume>116</volume>
<page-range>9S-15S</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hudson]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Progress in understanding ventilator-induced lung injury]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1999</year>
<volume>282</volume>
<page-range>77-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ranieri]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Slutzky]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Respiratory physiology and acute lung injury: the miracle of lazarus]]></article-title>
<source><![CDATA[Intesive Care Medicine]]></source>
<year>1999</year>
<volume>25</volume>
<page-range>1040-3</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Slutsky]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Gerstmann]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Lung protective strategies of ventilation in the neonate: what are they?]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>2000</year>
<volume>105</volume>
<page-range>112-4</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dreyfuss]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Saumon]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Ventilator-induced lung injury]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>1998</year>
<volume>157</volume>
<page-range>294-323</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Creamer]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[McCloud]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Ehrhart]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Closing pressure rather than opening pressure determines optimal positive end expiratory pressure and avoids overdistention]]></article-title>
<source><![CDATA[Chest]]></source>
<year>1999</year>
<volume>116</volume>
<page-range>26s-27s</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amato]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Barbas]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Medeiros]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of a protectiveventilation strategy on mortality in the acute respiratory distress syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1998</year>
<volume>338</volume>
<page-range>347-54</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<collab>The Acute Respiratory Distress Syndrome Network</collab>
<article-title xml:lang="en"><![CDATA[Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2000</year>
<volume>342</volume>
<page-range>1301-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taskar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[John]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Evander]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Jonson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Surfactant dysfunction makes lungs vulnerable to repetitive collapse and reexpansion]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>1997</year>
<volume>155</volume>
<page-range>313-20</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kolton]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cattran]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Kent]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Volgyesi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Froese]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Bryan]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Oxygenation during high-frequency ventilation compared with conventional mechanical ventilation in two models of lung injury]]></article-title>
<source><![CDATA[Anesth Analg]]></source>
<year>1982</year>
<volume>61</volume>
<page-range>323-32</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Froese]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[McCulloch]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Sugiura]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vaclavik]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Possmayer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Moller]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Optimizing alveolar expansion prolongs the effectiveness of exogenous surfactant therapy in the adult rabbit]]></article-title>
<source><![CDATA[Am Rev Respir Dis]]></source>
<year>1993</year>
<volume>148</volume>
<page-range>569-77</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doctor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mechanical support of acute lung injury: options for strategic ventilation]]></article-title>
<source><![CDATA[New Horizons]]></source>
<year>1999</year>
<volume>7</volume>
<page-range>359-73</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Manwell]]></surname>
<given-names><![CDATA[SEE]]></given-names>
</name>
<name>
<surname><![CDATA[Kerr]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Veldhuizen]]></surname>
<given-names><![CDATA[RAW]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bjarneson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of ventilation strategies on efficacy of exogenous surfactante therapy in a rabbit model lung injury]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>1997</year>
<volume>157</volume>
<page-range>149-55</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Veldhuizen]]></surname>
<given-names><![CDATA[RAW]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[McCaig]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barttlett]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Ventilation strategies affect surfactant aggregate conversion in acute lung injury]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>1997</year>
<volume>155</volume>
<page-range>493-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hatcher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ashbury]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Froese]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mechanical performance of clinically available neonatal, high-frequency, oscilatory-type ventilators]]></article-title>
<source><![CDATA[Crit Care Med]]></source>
<year>1998</year>
<volume>26</volume>
<page-range>1081-88</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCulloch]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Forkert]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Froese]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Lung volume maintenance prevents lung injury during high frequency oscillation in surfactant deficient rabbits]]></article-title>
<source><![CDATA[Am Rev Respir Dis]]></source>
<year>1988</year>
<volume>137</volume>
<page-range>1185-92</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thome]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Töpfer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Achaller]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pohlandt]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of mean airway pressure on lung volume during high-frequency oscillatory ventilation of preterm infants]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>1998</year>
<volume>157</volume>
<page-range>1213-18</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meredith]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
<name>
<surname><![CDATA[de Lemos]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Coalson]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Role of lung injury in pathogenesis of hyaline membrane disease in premature baboons]]></article-title>
<source><![CDATA[J Appl Physiol]]></source>
<year>1989</year>
<volume>66</volume>
<page-range>2150-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[PP]]></given-names>
</name>
<name>
<surname><![CDATA[Onayemi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Smyth]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Gillan]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Cutz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Froese]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparison of conventional and high-frequency ventilation: oxygenation and lung pathology]]></article-title>
<source><![CDATA[J Appl Physiol]]></source>
<year>1983</year>
<volume>55</volume>
<page-range>131-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takata]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Abe]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kitano]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Doi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Koshaka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Intra-alveolar expression of tumor necrosis factor gene during conventional and high frequency ventilation]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>1997</year>
<volume>156</volume>
<page-range>272-9</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cochrane]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Revak]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Surfactant lavage treatment in a model of respiratory distress syndrome]]></article-title>
<source><![CDATA[Chest]]></source>
<year>1999</year>
<volume>116</volume>
<page-range>85s-87s</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kerr]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Manwell]]></surname>
<given-names><![CDATA[SEE]]></given-names>
</name>
<name>
<surname><![CDATA[Veldhuizen]]></surname>
<given-names><![CDATA[RAW]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[McCaig]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of surfactant distribution and ventilation strategies on efficacy of exogenous surfactant]]></article-title>
<source><![CDATA[J Appl Physiol]]></source>
<year>1998</year>
<volume>85</volume>
<page-range>676-84</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bauman]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Willson]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Surfactant in pediatric respiratory failure]]></article-title>
<source><![CDATA[New Horizons]]></source>
<year>1999</year>
<volume>7</volume>
<page-range>399-413</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gregory]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Steinberg]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Spragg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Bovine surfactant therapy for patients with acute respiratory distress syndrome]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>1997</year>
<volume>155</volume>
<page-range>1309-15</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kruse]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Schült Mönting]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hoehn]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Rate of surfactant administration influences lung function and gas exchange in a surfactant-deficient rabbit model]]></article-title>
<source><![CDATA[Pediatr Pulmonol]]></source>
<year>1998</year>
<volume>25</volume>
<page-range>196-204</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hills]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[An alternative view of the role of surfactant and the alveolar model]]></article-title>
<source><![CDATA[J Appl Physiol]]></source>
<year>1999</year>
<volume>87</volume>
<page-range>1567-83</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kobayashi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ohta]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tashiro]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nishizuka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ohmura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Dextran restores albumin-inhibited surface activity of pulmonary surfactant extract]]></article-title>
<source><![CDATA[J Appl Physiol]]></source>
<year>1999</year>
<volume>86</volume>
<page-range>1778-84</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tauesch]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Goerke]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Clements]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nonionic polymers reverse inactivation of surfactant by meconium and other substances]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>1999</year>
<volume>159</volume>
<page-range>1391-5</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sohma]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brampton]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dunnill]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of ventilation with positive end-expiratory pressure on the development of lung damage in experimental acid aspiration pneumonia in the rabbit]]></article-title>
<source><![CDATA[Intensive Care Med]]></source>
<year>1992</year>
<volume>18</volume>
<page-range>112-7</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mechanisms of gas transport during ventilation by high frequency oscillation]]></article-title>
<source><![CDATA[J Appl Physiol]]></source>
<year>1984</year>
<volume>56</volume>
<page-range>553-63</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
